CSL to acquire Chinese blood plasma fractionator

The Australian blood plasma company buys a majority stake in a Chinese firm for $352 million in hopes of broadening its offering in China. It's the first such deal by a foreign firm.

Jill Mao

June 13, 2017

Australian blood plasma giant CSL is to strengthen its footprint in China with a $352 million deal for an 80 per cent stake in a Chinese plasma factionator.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

M&A
Disruption
North Asia
Australasia

#china
#health
#acquisitions
#csl
#ruide
#australia